# A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

> **NCT07107945** · PHASE3 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07107945
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-09
- **Primary completion:** 2028-06-26
- **Final completion:** 2029-06-25
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07107945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07107945, "A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07107945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*